Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The cardiotoxicity of antimalarial medicines has received renewed interest in recent years following the ‘Thorough QT’ assessment of the dihydroartemisinin-piperaquine formulation approved by the European Medicines Agency, which showed evidence of QT interval prolongation. Piperaquine is a bisquinoline antimalarial that is structurally related to chloroquine. Many drugs among the quinoline and structurally-related medicines affect myocardial depolarization and repolarization. WHO currently recommends the artemisinin-based combination treatment dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria. This treatment is being considered alongside other antimalarial medicines for preventive therapy and mass drug administration. To inform WHO recommendations, a group of experts met in October 2016 to review evidence on the cardiotoxicity risk of quinoline antimalarials and structurally-related medicines in people with and without clinical malaria. The following recommendations were proposed by the WHO Evidence Review Group for consideration by the WHO Malaria Policy Advisory Committee and the WHO Advisory Committee on Safety of Medicinal Products.




World Health Organization

Publication Date